Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.51 |
| ▸ | ACACA | Q13085 | 4/20 | 0.51 |
| ▸ | IKBKB | O14920 | 14/20 | 0.49 |
| ▸ | CHUK | O15111 | 5/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663255 | 0.84 | IKBKB (0.65) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4665059 | 0.84 | IKBKB (0.70) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4666771 | 0.83 | JAK2 (0.52) | ACACBACACAIKBKBCHUKAURKA | |
| SCHEMBL4663282 | 0.82 | HTR2B (0.44) | ACACBACACAIKBKBCHUKHTR2B | |
| SCHEMBL14030623 | 0.82 | IKBKB (0.47) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL6969942 | 0.71 | MAP3K12 (0.60) | ACACBACACAHTR2B | |
| SCHEMBL3389167 | 0.71 | JAK2 (0.49) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL13284192 | 0.70 | HDAC1 (0.47) | — | |
| SCHEMBL141661 | 0.70 | JAK2 (0.62) | — | |
| SCHEMBL142578 | 0.70 | JAK2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242685-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | claimed |
| US-20080242685-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
| EP-1940296-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007114848-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007114848-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242685-A1 | Chemical Compounds | NFKBIA, IKBKG, NFKB2 | ACACB 1271/4885ACACA 1715/4885IKBKB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.